Chronic lymphocytic leukemia hits older adults hardest. It starts in the bone marrow, the spongy stuff inside your bones. Too many lymphocytes pile up. These white blood cells multiply uncontrollably. The cancer moves slowly. You might not even know you have it.
Doctors often call this “watchful waiting.” If the disease is early-stage and symptom-free, treatment might cause more harm than good. No cure exists yet for chronic lymphocytic leukemia (CLL). But you can manage it. You can enter long-term remission. The path forward depends on your health, how advanced the cancer is, and your genetics.
You need testing to find the right drugs. Genetic changes in the tumor matter. Talk to your provider before mixing treatments. Here is how modern medicine tackles CLL today.
Why Watchful Waiting Comes First
If doctors catch CLL early, they may do nothing. Research shows that treating early-stage CLL does not improve survival rates. Why rush in? Unnecessary treatment brings side effects and complications.
Instead, your doctor monitors the disease. This is active surveillance. They wait. They watch for progression. Only then do they recommend action. It avoids the toxicity of drugs you might not need yet.
Targeted Therapy: Precision Strikes on Cancer Cells
When treatment becomes necessary, targeted therapy is usually the first line of defense. It focuses on specific proteins that help cancer cells grow and survive. These drugs often come as pills. You take them by mouth. Doctors may combine them with other therapies, but they often stand alone as the primary intervention.
BTK Inhibitors Block Growth Signals
These medicines block Bruton’s tyrosine kinase (BTK). This protein is essential for CLL cells to multiply.
- Acalabrutinib (Calquence)
- Ibrutinib (Imbruvica)
- Zanubrutinib (Brukinsa)
These are standard options for initial treatment. Pirtobrutinib (Jaypiraca) is another option. Doctors usually save it for cases where other treatments failed.
Side effects are real. They include bleeding, chills, fever, cough, and diarrhea. Fatigue sets in. Headaches occur. Heart problems can arise. You might face liver or kidney issues. Nausea, pain, and skin rash are common. There is also a risk of tumor lysis syndrome. This happens when cancer cells release their contents into your bloodstream. It is life-threatening.
BCL2 Inhibitors Target Survival Proteins
Venetoclax (Venclecta) is the key drug here. It targets the BCL2 protein. This protein helps CLL cells live longer than they should. Venetoclax stops that longevity. You take it as a pill.
Side effects overlap with other drugs: diarrhea, fatigue, infection risk, and low blood cell counts. Nausea and tumor lysis syndrome are also concerns.
Immunotherapy: Boosting Your Own Defenses
Immunotherapy ramps up your immune system. It helps your body identify and destroy cancer cells or slow their growth.
Monoclonal Antibodies Target CD20
These are lab-made versions of natural antibodies. They attach to proteins on cancer surfaces. This flags the cells for destruction. They are given via injection or IV. Doctors often pair them with targeted therapy or chemotherapy.
The targets focus on CD20, a protein found on CLL cells.
- Obinutuzumab (Gazywa)
- Ofatumumab (Arzerra)
- Rituximab (Rituxan)
Mild side effects include chills, constipation, fatigue, fever, headache, injection-site reactions, and nausea.
Sometimes, things go wrong. More serious symptoms can appear. Racing heart. Chest pain. Coughing fits. Dizziness. Trouble breathing. Swelling in the face or tongue. These are allergic or immune reactions.
Severe risks exist too. Stroke. Severe infections. Hepatitis B reactivation if you had it before. Progressive multifocal leukoencephalopathy, a rare brain infection. Tumor lysis syndrome again.
CAR T-Cell Therapy: Engineering Your T Cells
This approach is different. Doctors remove your T cells. They alter them in a lab, adding special receptors. They reinject these engineered cells back into your body. The new T cells multiply. They seek out cancer. They destroy it.
Lisocabtagene maraleucil (Breyanzi) is currently the only CAR T-cell option for CLL. It treats adults whose cancer has grown back or refuses to stop growing.
The risks are significant. Cytokine release syndrome can happen. Your immune system overreacts. Breathing problems, chills, fever, and weakness follow. You might suffer neurological issues. Confusion. Seizures. Tremors. Trouble speaking. Low blood cell counts. Serious infections. A weakened immune system.
Chemotherapy: The Old Guard, Still in the Arsenal
Chemotherapy kills cancer cells throughout the body. It used to be the go-to treatment for CLL. Not anymore. Targeted therapies and immunotherapy are often more effective and less toxic.
But chemo is still an option. When? If you need a quick response. If you can’t take other drugs. If those drugs stopped working. If you are getting a stem cell transplant.
Doctors might combine chemo with immunotherapy. This is chemoimmunotherapy. You receive it via IV or pill. It comes in cycles. Rest periods allow your body to recover.
Common drugs include:
* Bendamustine (Treanda)
* Chlorambucil (Leukeran)
* Cyclophosphamide (Cytozan)
* Fludarabine (Fludara)
Side effects are heavy. Easy bleeding or bruising. Fatigue. Frequent infections. Hair loss. Loss of appetite. Mouth sores. Nausea. Vomiting. Tumor lysis syndrome.
Stem Cell Transplant: A High-Risk Reset
Also called bone marrow transplant, this is for hard-to-treat CLL. Think chromosome 17 deletions or TP3 mutations. It’s not standard yet. Most transplants happen within clinical trials.
The process starts with chemotherapy. This wipes out your diseased bone marrow. Then, healthy stem cells from a donor are infused into your blood. They restore the marrow.
The risks are severe. Bleeding from low blood counts. Graft failure, where your body rejects the new cells. Graft-versus-host disease, where donor immune cells attack your body. Lung problems. Serious infections. Sinusoidal obstructive syndrome, blocking tiny blood vessels.
Radiation Therapy for Symptom Control
Radiation uses high-energy rays to destroy cancer cells. It’s not a primary cure for CLL. Instead, it manages symptoms. It lessens pain from an enlarged spleen or swollen lymph nodes?
Fatigue and skin irritation are the usual side effects.
Surgery: Rare but Necessary
Surgery isn’t common. But doctors might perform a splenectomy. They remove the spleen.
The spleen filters worn-out blood cells. With CLL, the spleen can swell and overwork. It removes too many blood cells. It puts pressure on nearby organs, causing pain.
Removing the spleen improves blood counts. It lessens symptoms. But it’s a last resort.
Clinical Trials: Access to the Next Wave
Clinical trials test safety and effectiveness. Many current treatments started here. Participating might give you access to novel therapies not yet public.
New drugs and combinations are on the horizon. Ask your doctor about finding a trial that fits you. It could be a way forward if standard options fail.
Lifestyle Changes for Better Management
You can’t prevent CLL. But you can manage it better. Small changes add up.
- Eat well. A Mediterranean-style diet helps. Fish. Fruits and vegetables. Legumes. Whole grains. This reduces cancer fatigue and improves overall health.
- Stay active. Regular exercise boosts immunity. Builds strength. Manages fatigue.
- Reduce stress. Diagnosis is stressful. Try deep breathing. Meditation. Relaxation exercises. Lower your stress levels.
- Avoid infection. Stay up to date on vaccinations. Wash your hands regularly. Prevent infections.
- Screen regularly. CLL increases the risk of other cancers. Colon. Lung. Skin. Don’t skip screenings. Early detection matters.
The landscape of CLL treatment is shifting. Targeted drugs have changed the game. But the path remains personal. What works for one person may not work for another. You have to weigh the side effects against the benefits. The science moves fast. New options emerge.
Talk to your doctor. Test your genetics. Monitor the disease. Wait if you need to. Treat when you must. There is no cure. But there is management. And for now, that is enough.
